Pharmacokinetics of ibopamine in patients with renal impairment

A. Salvadeo, G. Villa, G. Bovio, F. Pocchiari, R. Pataccini, A. Longo, G. P. Ventresca

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of a single oral dose of ibopamine 100 mg were studied in 15 patients with various degrees of chronic renal impairment (CRI) and in 8 subjects with normal renal function and of comparable age, taken as a control group. Plasma total (mainly conjugated) and free epinine and urinary metabolites (total epinine, HVA and DOPAC) were measured. Both total and free epinine were detectable at the earliest sampling time (15 min) in CRI patients and in normal subjects, thus confirming the promptness of ibopamine absorption. Free epinine pharmacokinetic parameters did not show any appreciable differences among the groups with different degrees of renal impairment, and no statistically significant differences were observed between normal subjects and CRI patients. Progressive renal impairment was associated with higher C(max,) longer t 1/2 and larger AUC∞ of total epinine, and with reduced urinary elimination of total epinine and metabolites. Statistically significant differences (p

Original languageEnglish
Pages (from-to)98-104
Number of pages7
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume26
Issue number2
Publication statusPublished - 1988

Fingerprint

Deoxyepinephrine
Pharmacokinetics
Kidney
Metabolites
3,4-Dihydroxyphenylacetic Acid
Area Under Curve
ibopamine
Sampling
Plasmas
Control Groups

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology

Cite this

Salvadeo, A., Villa, G., Bovio, G., Pocchiari, F., Pataccini, R., Longo, A., & Ventresca, G. P. (1988). Pharmacokinetics of ibopamine in patients with renal impairment. International Journal of Clinical Pharmacology Therapy and Toxicology, 26(2), 98-104.

Pharmacokinetics of ibopamine in patients with renal impairment. / Salvadeo, A.; Villa, G.; Bovio, G.; Pocchiari, F.; Pataccini, R.; Longo, A.; Ventresca, G. P.

In: International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 26, No. 2, 1988, p. 98-104.

Research output: Contribution to journalArticle

Salvadeo, A, Villa, G, Bovio, G, Pocchiari, F, Pataccini, R, Longo, A & Ventresca, GP 1988, 'Pharmacokinetics of ibopamine in patients with renal impairment', International Journal of Clinical Pharmacology Therapy and Toxicology, vol. 26, no. 2, pp. 98-104.
Salvadeo A, Villa G, Bovio G, Pocchiari F, Pataccini R, Longo A et al. Pharmacokinetics of ibopamine in patients with renal impairment. International Journal of Clinical Pharmacology Therapy and Toxicology. 1988;26(2):98-104.
Salvadeo, A. ; Villa, G. ; Bovio, G. ; Pocchiari, F. ; Pataccini, R. ; Longo, A. ; Ventresca, G. P. / Pharmacokinetics of ibopamine in patients with renal impairment. In: International Journal of Clinical Pharmacology Therapy and Toxicology. 1988 ; Vol. 26, No. 2. pp. 98-104.
@article{8d8652e516c74abcb725249b4a64fa3f,
title = "Pharmacokinetics of ibopamine in patients with renal impairment",
abstract = "The pharmacokinetics of a single oral dose of ibopamine 100 mg were studied in 15 patients with various degrees of chronic renal impairment (CRI) and in 8 subjects with normal renal function and of comparable age, taken as a control group. Plasma total (mainly conjugated) and free epinine and urinary metabolites (total epinine, HVA and DOPAC) were measured. Both total and free epinine were detectable at the earliest sampling time (15 min) in CRI patients and in normal subjects, thus confirming the promptness of ibopamine absorption. Free epinine pharmacokinetic parameters did not show any appreciable differences among the groups with different degrees of renal impairment, and no statistically significant differences were observed between normal subjects and CRI patients. Progressive renal impairment was associated with higher C(max,) longer t 1/2 and larger AUC∞ of total epinine, and with reduced urinary elimination of total epinine and metabolites. Statistically significant differences (p",
author = "A. Salvadeo and G. Villa and G. Bovio and F. Pocchiari and R. Pataccini and A. Longo and Ventresca, {G. P.}",
year = "1988",
language = "English",
volume = "26",
pages = "98--104",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0174-4879",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of ibopamine in patients with renal impairment

AU - Salvadeo, A.

AU - Villa, G.

AU - Bovio, G.

AU - Pocchiari, F.

AU - Pataccini, R.

AU - Longo, A.

AU - Ventresca, G. P.

PY - 1988

Y1 - 1988

N2 - The pharmacokinetics of a single oral dose of ibopamine 100 mg were studied in 15 patients with various degrees of chronic renal impairment (CRI) and in 8 subjects with normal renal function and of comparable age, taken as a control group. Plasma total (mainly conjugated) and free epinine and urinary metabolites (total epinine, HVA and DOPAC) were measured. Both total and free epinine were detectable at the earliest sampling time (15 min) in CRI patients and in normal subjects, thus confirming the promptness of ibopamine absorption. Free epinine pharmacokinetic parameters did not show any appreciable differences among the groups with different degrees of renal impairment, and no statistically significant differences were observed between normal subjects and CRI patients. Progressive renal impairment was associated with higher C(max,) longer t 1/2 and larger AUC∞ of total epinine, and with reduced urinary elimination of total epinine and metabolites. Statistically significant differences (p

AB - The pharmacokinetics of a single oral dose of ibopamine 100 mg were studied in 15 patients with various degrees of chronic renal impairment (CRI) and in 8 subjects with normal renal function and of comparable age, taken as a control group. Plasma total (mainly conjugated) and free epinine and urinary metabolites (total epinine, HVA and DOPAC) were measured. Both total and free epinine were detectable at the earliest sampling time (15 min) in CRI patients and in normal subjects, thus confirming the promptness of ibopamine absorption. Free epinine pharmacokinetic parameters did not show any appreciable differences among the groups with different degrees of renal impairment, and no statistically significant differences were observed between normal subjects and CRI patients. Progressive renal impairment was associated with higher C(max,) longer t 1/2 and larger AUC∞ of total epinine, and with reduced urinary elimination of total epinine and metabolites. Statistically significant differences (p

UR - http://www.scopus.com/inward/record.url?scp=0023949525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023949525&partnerID=8YFLogxK

M3 - Article

C2 - 3410592

AN - SCOPUS:0023949525

VL - 26

SP - 98

EP - 104

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0174-4879

IS - 2

ER -